ArticleJournal for immunotherapy of cancer2026

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

Hiroki Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.